A Perspective – can copper complexes be developed as a novel class of therapeutics?. Issue 33 (12th July 2017)

• Record Type: Journal Article
• Authors: Wehbe, Mohamed; Leung, Ada W. Y.; Abrams, Michael J.; Orvig, Chris; Bally, Marcel B.
• Is Part Of: Dalton transactions. Volume 46:Issue 33(2017)
• Page Start: 10758
• Page End: 10773
• Publication Date: 2017-07-12
• Subjects: Chemistry, Inorganic -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemistry, Inorganic -- Periodicals; 546.05
• DOI: 10.1039/c7dt01955f
• Languages: English
• ISSNs: 1477-9226

Abstract

Abstract : Copper complexes could define a promising new class of therapeutics, provided that there is a suitable way in which to formulate them for pharmaceutical use. Abstract : Although copper–ligand complexes appear to be promising as a new class of therapeutics, other than the family of copper(ii ) coordination compounds referred to as casiopeínas these compounds have yet to reach the clinic for human use. The pharmaceutical challenges associated with developing copper-based therapeutics will be presented in this article along with a discussion of the potential for high-throughput chemistry, computer-aided drug design, and nanotechnology to address the development of this important class of drug candidates.